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Objective  To investigate the eff  ect of radiofrequency (RF) sacral rhizotomy of the intolerable neurogenic bladder 
in spinal cord injured patients.
Method  Percutaneous RF sacral rhizotomy was performed on 12 spinal cord injured patients who had neurogenic 
bladder manifested with urinary incontinence resisted to an oral and intravesical anticholinergic instillation 
treatment. Various combinations of S2, S3, and S4 RF rhizotomies were performed. Th   e urodynamic study (UDS) 
was performed 1 week before RF rhizotomy. The voiding cystourethrogram (VCUG) and voiding diaries were 
compared 1 week before and 4 weeks after therapy. Total volume of daily urinary incontinence (ml/day) and clean 
intermittent catheterization (ml/time) volume of each time were also monitored.
Results  After RF sacral rhizotomy, bladder capacity increased in 9 patients and the amount of daily urinary 
incontinence decreased in 11 patients. The mean maximal bladder capacity increased from 292.5 to 383.3 ml 
(p<0.05) and mean daily incontinent volume decreased from 255 to 65 ml (p<0.05). Bladder trabeculation and 
vesicoureteral refl  ux fi  ndings did not change 4 weeks after therapy.
Conclusion  This study revealed that RF sacral rhizotomy was an effective method for neurogenic bladder with 
uncontrolled incontinence using conventional therapy among spinal cord injured patients.
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INTRODUCTION
Th   e neurogenic bladder of spinal cord injured patients 
is classifi  ed in several clinical aspects according to the in-
jury level and severity. Patients with neurogenic detrusor 
overactivity have compromised bladder storage volume 
and increased urinary incontinence due to elevated in-
travesical pressure.
To suppress the pressure of the detrusor muscle and to 
reduce the volume of urinary incontinence, anticholiner-
gic agents are frequently used as the treatment of choice 
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for neurogenic detrusor overactivity in spinal cord injury 
(SCI). At the same time, it also has side effects, such as 
dry mouth, constipation, nausea, and visual fi  eld defects. 
Moreover, some patients have a refractory response to 
the maximal dosage of oral medication.
1 To avoid the 
systemic side eff  ects of medication, intravesical anticho-
linergic instillation and botulinum toxin injection to the 
detrusor muscle are performed, but these therapies risk 
infection and need to be performed repeatedly because 
their eff  ects are not permanent.
2-4
Surgical treatments for the intolerable neurogenic blad-
der aim to reduce the pressure of the detrusor muscle 
and to prevent complications of the upper urinary tract. 
For this reason, augmentation cystoplasty, which directly 
expands the bladder volume using intestinal segments, 
has become a standard surgical option. An alternative to 
surgery is functional reconstruction of the hyperrefl  exic 
bladder using selective sacral rhizotomies. Selective 
sacral rhizotomy has benefits in improving the urinary 
incontinence and eliminating detrusor overactivity.
5 
Moreover, there are fewer complications compared to 
augmentation cystoplasty and intermittent catheteriza-
tion can be applied even if an areflexic bladder occurs. 
However, this procedure has certain drawbacks as well, 
such as a weakening of the urethral sphincter and pelvic 
fl  oor muscles, abolition of the refl  ex erection, and refl  ex 
ejaculation among males. In addition, because this inter-
vention is irreversible, it prevents spinal cord regenera-
tion.
6
Percutaneous radiofrequency (RF) sacral rhizotomy is 
considered a valid alternative with compensating surgical 
options. RF ablate the nerve by generating heat around 
the nervous tissue using high frequency waves, resulting 
in a denaturation of protein in nerve fi  bers. It is used to 
treat neuropathic pain, sympathetically maintained pain, 
and chronic spinal pain.
As a non-surgical method, RF sacral rhizotomy is used 
in managing trigeminal neuralgia stellate ganglion block, 
spinal nerve block, and percutaneous dorsal rhizotomies. 
It also has the benefi  ts of simplicity, safety, short hospital 
stay, and few complications.
7
Th   ere have been reports of RF sacral rhizotomy reduc-
ing the pressure of the detrusor muscle and increasing 
the bladder volume;
8,9 however, a specifi  c and quantifi  ed 
research on the bladder maximum volume and variety 
of conformation has not been reported. The aim of this 
study is to determine the signifi  cant and clinical eff  ects of 
percutaneous RF sacral rhizotomy as a treatment of neu-
rogenic bladder in SCI by observing the improvement of 
urinary incontinence and bladder volume through com-
paring before and after the procedure.
MATERIALS AND METHODS
Subjects
From March 2006 to July 2011, twelve spinal cord in-
jured patients (11 males and 1 female, mean age of 
49.7±11.9) was presented at Chungnam National Univer-
sity Hospital for the treatment of neurogenic bladder. Th  e 
patients suffered from frequent urination and urinary 
incontinence though anticholinergic medicine was ad-
ministered over 6 months. The subjects took a maximal 
dosage of multiple oral medications at acceptable levels 
to avoid side eff  ects. According to the UDS, the maximum 
cystometric capacity of the subjects was under 300 ml 
and compliance was under 15 ml/cmH2O. Of the 12 pa-
tients, 11 patients were diagnosed with neurogenic detru-
sor overactivity and one patient was diagnosed with de-
trusor areflexia. The mean interval between occurrence 
of injury and UDS was 54.1±43.7 months. Four patients 
were injured at the cervical level, seven patients at the 
thoracic level, and one patient was injured at the lumbar 
Table 1. Characteristics of the Patients with Spinal Cord 
Injury
Patient
Age/
Sex
Level (ASIA 
impairment 
scale)
Time since 
injury 
(months)
Voiding 
method
  1 34/F   C4 (B)   60 CIC
  2 46/M   C6 (D)   12 Self voiding
  3 52/M T10 (A)     7 CIC
  4 53/M   T5 (A)   88 CIC
  5 28/M   T4 (A)   28 CIC
  6 69/M   L1 (A)   39 Diaper voiding
  7 60/M   C4 (A)   76 CIC
  8 49/M T10 (A)   16 CIC
  9 37/M   T4 (B) 120 Self voiding 
10 51/M   T8 (A)   34 CIC
11 62/M   T3 (A) 142 CIC
12 55/M   C4 (A)   32 CIC
ASIA: American spinal injury association, CIC: Clean 
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215 www.e-arm.org
level. A complete injury was observed in 9 patients and 
incomplete injury in 3 patients (Table 1). Nine patients 
urinated by performing intermittent catheterization (IC) 
and 3 patients urinated by self-voiding control. Exclusion 
criteria included patients who had urinary tract disease 
before SCI or had their urinary tract operated. Th  e  sub-
jects did not change their bladder medication during 
their study participation. 
Methods
All subject underwent voiding cystourethrogram 
(VCUG) and UDS 1 week before a percutaneous RF sacral 
rhizotomy was performed. Four weeks after the proce-
dure, a repeat VCUG was done. From 1 week before to 4 
weeks after the procedure, a voiding diary was collected 
from each enrolled patient. It included a recording of the 
total amount of daily water intake and output, daily aver-
age CIC volume, residual urine, intervals of urination, 
and daily urinary incontinence volume. Incontinence 
volume was recorded by measuring the weight of diapers.
 Duet
® LOGIC G2 (Mediwatch Plc, FL, USA) was used 
for the UDS measuring the maximum cystometric capac-
ity, compliance, and detrusor pressure at the maximum 
cystometric capacity during the storage phase. Th  e  blad-
der was fi  lled with 60 ml/min of warm saline (20-30
oC). 
Maximum cystometric capacity was determined as the 
total amount of filling saline when leakage occurred. 
Detrusor pressure at the maximum cystometric capac-
ity was determined by the difference between maximal 
intravesical pressure and abdominal pressure. Measuring 
the pressure in the bladder using double lumen catheter 
and abdominal pressure was recorded through a rectal 
probe. Compliance is determined by a change in volume 
divided by a change in baseline pressure with fi  lling.
To evaluate the bladder function by VCUG, the blad-
der was filled with 36°C of normal saline with contrast. 
Maximal bladder volume and bladder trabeculation were 
evaluated at a fi  lling phase in the period before micturi-
tion. Maximal bladder volume was determined when 
leakage occurred or the catheter was forced out. Vesico-
ureteral refl  ux was evaluated at a voiding phase inducing 
micturition with suprapubic tapping or compression. 
Th   e RF was performed at bilateral S2 or S3 roots. If there 
was diffi   culty with approaching S2 or S3 foramen, the S4 
root was considered. Subjects were fully informed of the 
risks and side effects that they might experience during 
this procedure. In a prone position, a 22 gauge needle 
and stylet was inserted on the skin surface to the sacral 
roots of the S2, S3, and S4 levels under fluoroscopic 
guidance (Fig. 1). Next, the stylet was removed from the 
needle and an electrode connecting NT1000 was inserted 
(Neurotherm Inc, MA, US). Th   e bilateral sacral root was 
initially identified through a stimulating pulse of 2 Hz, 
0.2 V. The voltage progressively increased by 0.8 V until 
contraction of the multifidus close to the sacrum could 
be seen and contraction of the lower extremity muscles 
could not be seen. Impedance was 300-1,000 Ω. Th  e  ther-
molesion was performed 90-120 seconds at 90
oC. 
Maximum cystometric capacity, compliance, and de-
trusor pressure of the maximum cystometric capacity 
during UDS were measured before RF sacral rhizotomy 
began. Maximal bladder capacity, vesicoureteral reflux, 
Fig. 1. Selective nerve root infiltra-
tion of S2 root. Left anteroposterior 
roenterogram shows the proper 
placement of the spinal needles at S2 
sacral foramen for radiofrequency 
sacral rhizotomy. Right side shows 
the outline of S2 nerve root by the 
contrast material.Kang Hee Cho and Sang Sook Lee
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and bladder trabeculation by VCUG were compared 
before and after procedure. Bladder trabeculation was 
classified by 4 groups based on severity and morphol-
ogy (Grade 0: none bladder trabeculation, Grade 1: slight 
to moderate, Grade 2: severe, and Grade 3: severe with 
formation of diverticula).
10 Th   e average CIC volume and 
total amount of daily incontinence using a self-reported 
voiding diary were compared before and after treatment.
Wilcoxon Signed Ranks test was used to compare blad-
der capacity before and after percutaneous RF sacral 
rhizotomy, and Spearman correlation was performed to 
evaluate the association between period of time since 
injury and effi   cacy of rhizotomy. Statistical analysis was 
carried out with SPSS version 12.0. A p<0.05 level was 
considered signifi  cant.
RESULTS
Voiding diary: comparison of the average CIC volume 
and total amount of daily incontinence before and 
after percutaneous RF sacral rhizotomy
Th   e average clean intermittent catheterization volume 
increased from 303.7±109.1 ml to 467.2±134.4 ml (p<0.05) 
and total amount of daily incontinence decreased from 
254.9±68.1 ml to 65.2±91.3 ml (p<0.05). Intervals of uri-
nation increased in all cases and urinary incontinence 
improved in 11 cases (Table 2).
VCUG: comparison of the maximal bladder capacity, 
vesicoureteral reﬂ  ux, and bladder trabeculation before 
and after percutaneous RF sacral rhizotomy
Among the 12 patients, 10 increased maximal bladder 
capacity. Maximum bladder capacity increased from 
295.5±137.1 ml to 383.3±190.4 ml (p<0.05). Th   ere were no 
significant differences regarding the duration of SCI or 
neurologic level of injury.
In 1 patient, who was observed bilateral VUR (Grade I), 
VUR grade did not change. Based on bladder trabeculai-
on grade, two patients were in Grade 0, six were in Grade 
1, and four were in Grade 3. There were no significant 
changes of bladder trabeculation grade after the proce-
dure (Table 3).
Table 2. Comparison of Clinical Parameters before and 
after Radiofrequency Sacral Dorsal Rhizotomy
Parameter Before After
Average CIC volume of each time (ml) 304±109 467±134*
Total amount of incontinence (ml) 255±68 65±91*
Values are mean±standard deviation
CIC: Clean intermittent catheterization
*p<0.05
Table 3. Comparison of Voiding Cystourethrographic Findings before and after Radiofrequency Sacral Dorsal Rhizo-
tomy
Patient
Before After
Maximal bladder 
capacity (ml)
Trabeculation 
(Grade)
Maximal bladder 
capacity (ml)
Trabeculation 
(Grade)
  1 100 0 270 0
  2 300 1 500 1
  3 540 1 600 1
  4 300 1 750 1
  5 550 0 300 0
  6 200 3 250 3
  7 300 1 480 1
  8 180 3 250 3
  9 300 1 380 1
10 160 1 240 1
11 330 3 200 3
12 250 3 130 3Radiofrequency Sacral Rhizotomy for the Management of Intolerable Neurogenic Bladder
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UDS: The maximum cystometric capacity, compliance, 
and detrusor pressure at the maximum cystometric 
capacity before percutaneous RF sacral rhizotomy
The maximum cystometric capacity was 263.1±192.4 
ml, compliance was 5±5.8 ml/cmH2O, and detrusor pres-
sure at the maximum cystometric capacity was 44.9±32.7 
cmH2O. 
DISCUSSION
Th   e purpose of neurogenic bladder management in spi-
nal cord injured patients is to maintain pressure of detru-
sor and minimize residual urine for normal urinary blad-
der function, and consequently preserving renal function 
and decreasing urinary tract complications.
11 Most of the 
patients with neurogenic detrusor overactivity can be 
treated using an anticholinergic agent, with or without si-
multaneous CIC. However, these medications can cause 
dry mouth, constipation, nausea, and visual fi  eld defects. 
This is particularly the case of conservative refractory 
patients who are in need of alternative management.
1 To 
reduce these side eff  ects, Ekstrom et al.
4 performed an in-
travesical instillation of atropine and phentolamine. Shin 
et al.
20 demonstrated that an administration of intravesi-
cal oxybutynin improved maximal bladder capacity and 
compliance, as well as lowered maximal detrusor pres-
sure. They added that this could be a safe and effective 
alternative management of neurogenic bladder in SCI.
2,4 
However, there were problems, including a discomfort in 
the vesicle, infection of urinary tract, and temporary ef-
fect of improving compliance. Th   e treatment of Capsaicin 
and Resinferatoxin in the neurogenic bladder increases 
the maximal bladder volume and compliance, and de-
creases the maximal detrusor muscle pressure. However, 
treatment of capsaicin irritates the bladder wall, leading 
to pain. Hence, this method is not generally accepted in 
clinical practice. Resinferatoxin has a similar eff  ect with 
the Capsaicin treatment and does not induce pain in pa-
tients, but it is diffi   cult for patients to use the drugs and 
its eff  ectiveness is very short in duration.
12,13 Th  e  stretch 
therapy of bladder can increase the maximal bladder 
volume in a short time and attenuate the symptoms of 
urinary incontinence. However, it causes the bladder to 
disrupt and infect the urinary tract. Th   ere is also a lack of 
long-term clinical test fi  ndings.
2,14-16
Schurch et al. has reported the management of direct 
injection of Botulinium toxin A in the detrusor muscle 
of the neurogenic bladder in SCI patients to alleviate the 
discomfort of irritation and urinary tract infection. Th  ey 
demonstrated that the injection significantly increased 
the maximal bladder volume and decreased the intrave-
sicular pressure and frequency of urinary incontinence. 
However, they did not mention the long-term effects of 
treatment, after 6 months; thus, the duration of Botuli-
num toxin A’s clinical eff  ects remain uncertain.
3
Surgical treatment is also considered for intolerable 
neurogenic bladder. It is eff  ective in reducing urinary in-
continence and increasing maximal bladder capacity by 
controlling detrusor hyperactivity. However, this surgi-
cal procedure destroys nerve fi  bers irreversibly, it aff  ects 
the regeneration of spinal nerves, it weakens the urethral 
sphincter and pelvic fl  oor muscles, and it suppresses re-
fl  ex erection and refl  ex ejaculation in males.
5,6
RF uses heat to ablate the nervous tissue and produces 
electrodes with an oscillating high frequency. RF disrupts 
the nervous tissues surrounding the electrode non-selec-
tively. It can regulate the lesioning by thermoregulation. 
It makes coagulated lesion, which blocks the nerve con-
duction under 45
oC, and ablate nervous tissue irrevers-
ibly over 45
oC.
17
In this study, RF was used to ablate the parasympathetic 
nervous system at the S2-S4 in the same manner with os-
cillating high frequency electrode. A lower urinary tract is 
controlled by the parasympathetic and somatic nervous 
system at S2-S4 and the sympathetic nervous system at 
T11-L2. It is based on controlling bladder function that 
cooperates with voiding refl  exes by sacral refl  ex arcs and 
detrusor-sphincter synergia by brain stem cortical inhibi-
tion through the micturitional reflex center. Sensations 
of the bladder and urethra are transported to the central 
nervous system by the somatic and autonomic nervous 
systems. Bladder fi  lling triggers stretch receptors distrib-
uted at the detrusor muscles and signals are transmit-
ted to the sacral reflex centers by sympathetic nerves.
18 
Successful bladder denervation in the form of RF sacral 
rhizotomies of the S2-S4 segments for the treatment of 
neurogenic detrusor overactivity was first described by 
Mulcahy et al.
8,9 Since Ferreira et al.
19 was successful in 
increasing bladder capacity and decreasing intravesical 
pressure at the bilateral S3 level of RF sacral rhizotomy, 
we have attempted to interrupt the bilateral S2 or S3 
roots. If there were diffi   culties approaching S2 or S3 roots Kang Hee Cho and Sang Sook Lee
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due to bowel gas or anatomical problem, S4 root were 
targeted. Eleven patients diagnosed with UDS neurogenic 
detrusor overactivity had increased maximal bladder vol-
ume and intervals of urination and decreased urinary in-
continence after RF. One patient who was diagnosed with 
UDS detrusor areflexia, but had vesicoureteral reflux, 
urinary frequency, and incontinence, also had improved 
clinical symptoms and maximal bladder capacity.
RF sacral rhizotomy is a procedure that is only mini-
mally invasive, possible to perform repeatedly, reduces 
side eff  ects of the urinary tract, is safe for regional infec-
tion, costs minimally, has a shortened hospital recovery 
period, and provides a faster return to daily activities. 
Furthermore, because this procedure takes longer for the 
injured nerve to recover than traumatic nerve damage, it 
will be helpful to keep up with these treatment eff  ects for 
a period of time. In this study, 3 of the 12 patients were 
evaluated by the VCUG after 1 year of procedure. Con-
sistent with our expectations, 2 patients had maintained 
their maximal bladder volume and 1 patient experienced 
an increase. The rest of the patients had missed long-
term follow-ups due to low compliance or did not reach 1 
year after procedure. To evaluate the long-term eff  ects of 
therapy, more patients are needed beyond the one year 
of therapy period for the study to provide meaningful 
clinical result.
In this study, 17% of the enrolled patients have de-
creased maximal bladder volume in VCUG. However, 
clinical maximal bladder volume, average CIC volume, 
and intervals of urination increased and quantity of in-
continence decreased in all treated patients. Moreover, 
none of the patients had pain, focal discomfort in the 
treated region, or sexual dysfunction. Based on these re-
sults, RF is safe, has few complications, and valid for neu-
rogenic bladder by decreasing the incontinence and in-
creasing the bladder volume. One limitation of our study 
was in not evaluating the long-term effects of detrusor 
pressure and compliance. Further studies are needed to 
identify the long-term effects of radiofrequency sacral 
rhizotomy to neurogenic detrusor overactivity.
CONCLUSION
This study confirms the potential efficacy of percuta-
neous RF sacral rhizotomy in reducing urinary inconti-
nence and increasing the bladder volume to neurogenic 
detrusor overactivity. No areflexic bladder, sphincter 
dysfunction, or sexual complication occurred. Th  erefore, 
percutaneous RF sacral rhizotomy is a safe and valuable 
treatment option for neurogenic detrusor overactivity in 
SCI. 
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